June 4th 2023
The results show intraindividual variability in total sleep time, time in bed, midpoint sleep, bedtime, and risetime were associated with lower sleep quality.
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
Managing Bipolar Disorder: The Pharmacist’s Role in Delivering Quality Care
1.0 Credits / Psychiatry
The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
1.5 Credits / Neurology, Psychiatry
Continuing the Conversation: Advancements in Integrated Continuous Glucose Monitoring Devices and Best Practices to Customize Care (Technician Credit)
2 Credits / Endocrinology
Continuing the Conversation: Advancements in Integrated Continuous Glucose Monitoring Devices and Best Practices to Customize Care
2 Credits / Endocrinology
Promoting Adherence in Early-Stage HR+/HER2- Breast Cancer: The Value of Oncology Pharmacists in Preventing Premature Treatment Discontinuation
1.25 Credit(s) / Oncology; Women’s Health
A Pharmacologic Overview of Antibody-Drug Conjugates
2.0 Credits / Oncology
Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure
1.0 Credit / Oncology
Even With High Proteinuria, Voclosporin Proves Benefit in Lupus NephritisJune 4th 2023
An analysis of data from the phase 2 AURA-LV and phase 3 AURORA 1 trials provides new insight into the effects of voclosporin for the treatment of active lupus nephritis in patients with high proteinuria.
Xenofon Baraliakos, MD, PhD: Efficacy of Upadacitinib for Treating Active Ankylosing SpondylitisJune 3rd 2023
Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.
Iain McInnes, CBE, PhD: Long-Term Efficacy, Safety of Upadacitinib in Patients With Psoriatic ArthritisJune 3rd 2023
Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.
Genetic Variants in STAT4 Linked to Disabling Pansclerotic Morphea: JAK Inhibition Shows Promising ResultsJune 2nd 2023
Gain-of-function STAT4 variants in patients with disabling pansclerotic morphea suggest a potential therapeutic role for JAK inhibition, resulting in improved clinical symptoms and inflammatory markers.
Pegloticase Use Could Contribute to Bone Remodeling in Gout PatientsJune 2nd 2023
An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.